The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity
In this interview, John Allan, MD, Weill Cornell Medicine, New York, NY, introduces the BruVenG trial (NCT05650723) of zanubrutinib and venetoclax as initial therapy for chronic lymphocytic leukemia (CLL), with obinutuzumab consolidation in patients with measurable residual disease (MRD) positivity. This is a response adapted trial which will test MRD status of patients following one year of combination therapy of zanubrutinib plus venetoclax once daily, after which those who are MRD-negative will terminate therapy and those who are MRD-positive will continue treatment for a further six cycles, with the addition of anti-CD20 therapy (obinutuzumab). Reserving obinutuzumab for consolidation is expected to mitigate the toxicities and overtreatment with the anti-CD20 antibody which are often seen in patients. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
